Stockscreener 앱 받기
7.17
2.58%
-0.19
시간 외 거래:
7.12
-0.05
-0.70%
전일 마감가:
$7.36
열려 있는:
$7.37
하루 거래량:
4.67M
Relative Volume:
0.83
시가총액:
$1.86B
수익:
$6.28B
순이익/손실:
$700.00M
주가수익비율:
2.6632
EPS:
2.6922
순현금흐름:
$537.00M
1주 성능:
+0.42%
1개월 성능:
-7.00%
6개월 성능:
-28.80%
1년 성능:
-53.29%
1일 변동 폭
$7.05
$7.39
1주일 범위
$6.90
$7.49
52주 변동 폭
$6.18
$17.23
오가논 & Co Stock (OGN) Company Profile
명칭
Organon Co
전화
551-430-6000
주소
30 HUDSON STREET, JERSEY CITY
OGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
7.17 | 1.91B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
1,027.51 | 903.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
211.58 | 505.98B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
223.32 | 395.86B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.57 | 253.97B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.30 | 245.75B | 63.90B | 19.05B | 13.05B | 7.5596 |
오가논 & Co Stock (OGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-10-27 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-09-06 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-11-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-09-21 | 개시 | Barclays | Overweight |
| 2023-03-16 | 개시 | Raymond James | Outperform |
| 2022-10-14 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-09-06 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 개시 | Piper Sandler | Neutral |
| 2021-09-01 | 개시 | BofA Securities | Buy |
| 2021-07-22 | 개시 | Citigroup | Buy |
| 2021-06-15 | 개시 | JP Morgan | Neutral |
| 2021-06-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 개시 | Evercore ISI | Outperform |
모두보기
오가논 & Co 주식(OGN)의 최신 뉴스
Is Trending Stock Organon & Co. (OGN) a Buy Now? - Yahoo Finance
Organon Shares Under Pressure Following Critical Analyst Review - Ad-hoc-news.de
Can Organon’s Steep 2025 Share Price Slide Signal a Long Term Opportunity? - simplywall.st
Organon pushes bold women’s health agenda at WHX Leaders’ Summit in Accra - MyJoyOnline
Les billets sont maintenant en vente pour Importance Vitale : sommet national sur la santé des femmes - GlobeNewswire Inc.
Why Organon (OGN) shares are trading lower today - MSN
Understanding Momentum Shifts in (OGN) - news.stocktradersdaily.com
Investors in Organon & Co. (OGN): Protect Your RightsContact Levi & Korsinsky Before July 22, 2025 - ACCESS Newswire
WHX Africa Leaders Summit: Organon Unveils Multi-Sector Approach to Women’s Health in Africa - News Ghana
Barclays Initiates Coverage of Organon (OGN) with Underweight Recommendation - Nasdaq
Why Organon (OGN) Shares Are Trading Lower Today - The Globe and Mail
Organon (OGN) Receives New Coverage with 'Underweight' Rating fr - GuruFocus
Barclays Initiates Coverage on Organon & Co. (NYSE:OGN) - MarketBeat
Norges Bank Takes $19.78 Million Position in Organon & Co. $OGN - MarketBeat
Organon initiated with an Underweight at Barclays - TipRanks
American Century Companies Inc. Grows Position in Organon & Co. $OGN - MarketBeat
What analysts say about Organon Co stockFederal Reserve Announcements & Outstanding Growth Strategies - earlytimes.in
A Closer Look At Organon & Co.'s (NYSE:OGN) Impressive ROE - 富途牛牛
Can Organon (OGN) Turn Rising Investor Attention Into a Durable Reboot of Its Core Story? - simplywall.st
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Co. (7XP) stock compared to peersPortfolio Update Report & Precise Buy Zone Identification - Newser
Organon & Co. $OGN Shares Acquired by Brandes Investment Partners LP - MarketBeat
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - MSN
Russell Investments Group Ltd. Has $15.96 Million Stock Position in Organon & Co. $OGN - MarketBeat
Can Organon’s (OGN) Biosimilar Push Transform Its Competitive Position in US Oncology? - Yahoo Finance
A Look at Organon's Valuation Following FDA Approval of First US Pertuzumab Biosimilar - Yahoo Finance
Is Organon’s Recent 14% Price Jump Justified After Women’s Health Partnership News? - Yahoo Finance
What analysts say about Organon Co 7XP stockShort Interest Overview & Grow Steadily With Our Wealth Roadmap - earlytimes.in
Organon (OGN): Buy, Sell, or Hold Post Q3 Earnings? - The Globe and Mail
Grantham Mayo Van Otterloo & Co. LLC Buys 108,429 Shares of Organon & Co. $OGN - MarketBeat
Avoiding Lag: Real-Time Signals in (OGN) Movement - news.stocktradersdaily.com
Organon (OGN): Exploring Valuation Following FDA Approval of First US Pertuzumab Biosimilar - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Organon & Co. $OGN Shares Sold by Envestnet Asset Management Inc. - MarketBeat
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman - The National Law Review
Creative Planning Buys 97,429 Shares of Organon & Co. $OGN - MarketBeat
Advisors Asset Management Inc. Sells 64,625 Shares of Organon & Co. $OGN - MarketBeat
Is Organon Co 7XP a good long term investmentLong-Term Investment Plans & High Yield Investment Portfolio - earlytimes.in
Organon & Co. $OGN Shares Sold by Geode Capital Management LLC - MarketBeat
Q3 Rundown: Organon (NYSE:OGN) Vs Other Branded Pharmaceuticals Stocks - The Globe and Mail
EXTENDED CLASS PERIOD: Organon & Co. (OGN) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit (PR Newswire) - Aktiellt
TUESDAY INVESTOR DEADLINE: Organon & Co. (OGN) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit (PR Newswire) - Aktiellt
Congressional Trading Report: Sen. Gary C Peters Sold Over $1K In Organon Stock - Sahm
Organon (NYSE: OGN) leaders to speak at Piper Sandler 37th Annual Healthcare Conference - Stock Titan
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference - Barchart.com
Organon & Co.Gary C. Peters Congressional Trade on Jul. 10, 2025 - Quiver Quantitative
Organon’s Deep Discount Comes With a Heavy Dose of Risk - Finimize
Can OGN’s First US Biosimilar Approval Redefine Its Long-Term Oncology Strategy? - Sahm
Organon and QC LGU empower women to ‘Take Control’ on World Contraception Day - Inquirer.net
Organon announces departure of chief commercial officer - MSN
Kingsview Wealth Management LLC Acquires New Position in Organon & Co. $OGN - MarketBeat
오가논 & Co (OGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.37%
0.19%
자본화:
|
볼륨(24시간):